One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Post-COVID dermatology�life will continue to be exciting
Johannes Ring
doi : 10.1111/jdv.19052
Adjuvant treatment in advanced melanoma: How far have we come?
V. Nikolaou, A. J. Stratigos
doi : 10.1111/jdv.19010
Advanced melanoma�A curable disease? Implications of systemic treatment on patients' daily life
Kai-Martin Thoms
doi : 10.1111/jdv.19018
Pioneers in Dermatology and Venereology: An Interview with Professor Can Baykal
Can Baykal
doi : 10.1111/jdv.19021
Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis
Alexander H. R. Varey, Gabrielle J. Williams, Serigne N. Lo, Cecilia Y. Taing, Andrea Maurichi, Mario Santinami, Richard A. Scolyer, John F. Thompson
doi : 10.1111/jdv.18665
Little guidance is currently available for managing patients with melanocytic tumours of uncertain or low malignant potential (MelTUMPs, including melanocytomas), in particular the optimal excision margins and whether to offer sentinel node biopsy (SNB).
Lentigo maligna (melanoma): A systematic review and meta-analysis on surgical techniques and presurgical mapping by reflectance confocal microscopy
Y. S. Elshot, D. C. K. S. Tio, A. S. E. van Haersma-de With, W. Ouwerkerk, B. Zupan-Kajcovski, M. B. Crijns, C. E. J. M. Limpens, W. M. C. Klop, M. W. Bekkenk, A. J. M. Balm, M. A. de Rie
doi : 10.1111/jdv.18880
Because of an increased risk of local recurrence following surgical treatment of lentigo maligna (melanoma) (LM/LMM), the optimal surgical technique is still a matter of debate.
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study
Alexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, Jessica C. Hassel, Imke Grimmelmann, Ralf Gutzmer, Max Schlaak, Markus V. Heppt, Pia Dücker, Svea Hüning, Lena Schulmeyer, Bastian Schilling, Sebastian Haferkamp, Mirjana Ziemer, Rose K. C. Moritz, Victoria Hagelstein, Patrick Terheyden, Christian Posch, Maria R. Gaiser, Peter Kropp, Steffen Emmert, Britta Müller, Julia K. Tietze
doi : 10.1111/jdv.18778
Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Katharina Schumann, Cornelia Mauch, Kai-Christian Klespe, Carmen Loquai, Ulrike Nikfarjam, Max Schlaak, Larissa Akçetin, Peter Kölblinger, Magdalena Hoellwerth, Markus Meissner, Guelcin Mengi, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Joanna Mangana, Mihaela-Anca Sindrilaru, Dan Radmann, Christine Hafner, Johann Freund, Klemens Rappersberger, Felix Weihsengruber, Frank Meiss, Lydia Reinhardt, Friedegund Meier, Barbara Rainer, Erika Richtig, Julia Maria Ressler, Christoph Höller, Thomas Eigentler, Teresa Amaral, Wiebke K. Peitsch, Uwe Hillen, Wolfgang Harth, Fabian Ziller, Kerstin Schatton, Thilo Gambichler, Laura Susok, Lara Valeska Maul, Heinz Läubli, Dirk Debus, Carsten Weishaupt, Sevil Börger, Katharina Sievers, Sebastian Haferkamp, Veronika Zenderowski, Van Anh Nguyen, Marina Wanner, Ralf Gutzmer, Patrick Terheyden, Katharina Kähler, Steffen Emmert, Alexander Thiem, Michael Sachse, Silke Gercken-Riedel, Kjell Matthias Kaune, Kai-Martin Thoms, Lucie Heinzerling, Markus Vincent Heppt, Sabine Tratzmiller, Wolfram Hoetzenecker, Angela Öllinger, Andreas Steiner, Tobias Peinhaupt, Maurizio Podda, Sabine Schmid, Uwe Wollina, Tilo Biedermann, Christian Posch
doi : 10.1111/jdv.18779
Programmed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high-risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real-world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland.
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy
Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode
doi : 10.1111/jdv.18847
Worldwide mass vaccination for COVID-19 started in late 2020. COVID-19 vaccines cause benign hypermetabolic lymphadenopathies. Clinical stratification between vaccine-associated benign lymphadenopathies and malignant lymphadenopathies through ultrasound, MRI or FDG PET-CT is not feasible.
Analysis of dermoscopic changes of blue nevi on digital follow-up: A 21-year retrospective cohort study
Francesc Alamon-Reig, Marc Combalia, Raquel Albero-González, Llúcia Alòs, Cristina Carrera, Joan Anton Puig-Butillé, José Luis Villanueva-Cañas, Susana Puig, Josep Malvehy, Sebastian Podlipnik
doi : 10.1111/jdv.18915
Blue nevi are benign dermal melanocytic proliferations that are often easy to recognize clinically. Rarely, these lesions can display atypical features, suggesting the presence of a malignant blue nevus or mimicking cutaneous metastases of melanoma.
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres
Alexander Troesch, Magdalena Hoellwerth, Stephan Forchhammer, Laura Del Regno, Georg Lodde, Patrick Turko, Phil F. Cheng, Mitchell L. Levesque, Eva Hadaschik, Elisabeth Livingstone, Ketty Peris, Lukas Flatz, Peter Koelblinger, Reinhard Dummer, Florentia Dimitriou
doi : 10.1111/jdv.18953
The COVID-19 lockdown had a dramatic impact on primary care access and resulted in postponed skin cancer screenings. This raises concerns for a diagnostic delay on primary cutaneous melanomas, which can subsequently increase morbidity and mortality.
Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019
Gabriella Liszkay, Angela Benedek, Csaba Polgár, Judit Oláh, Péter Holló, Gabriella Emri, András Csejtei, István Kenessey, Zoltán Polányi, Kata Knollmajer, Máté Várnai, Zoltán Vokó, Balázs Nagy, György Rokszin, Ibolya Fábián, Zsófia Barcza, Rolland Gyulai, Zoltan Kiss
doi : 10.1111/jdv.18960
Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking.
Cutaneous melanoma metastases: Clinical and dermoscopic findings
Maria Kostaki, Michaela Plaka, Margarita Moustaki, Aggeliki Befon, Grigoris Champsas, Katerina Kypreou, Vasiliki Chardalia, Vasiliki Chasapi, Dorothea Polydorou, Alexandros Stratigos
doi : 10.1111/jdv.18701
About 2%–20% of melanoma patients will develop cutaneous melanoma metastases (CMM). Their clinical diagnosis still remains challenging because of the variation of clinical and dermoscopic characteristics. Until today, few studies exist concerning the dermoscopic image of CMM but no one has focused on its possible association with clinicopathological melanoma characteristics.
3D Whole-body skin imaging for automated melanoma detection
M. A. Marchetti, Z. H. Nazir, J. K. Nanda, S. W. Dusza, B. M. D'Alessandro, J. DeFazio, A. C. Halpern, V. M. Rotemberg, A. A. Marghoob
doi : 10.1111/jdv.18924
Existing artificial intelligence for melanoma detection has relied on analysing images of lesions of clinical interest, which may lead to missed melanomas. Tools analysing the entire skin surface are lacking.
Solar elastosis and melanoma-specific survival: A systematic review and meta-analysis
Hua-Ching Chang, Henry Yi Cheng, Leon Tsung-Ju Lee
doi : 10.1111/jdv.18684
Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa
P. V. Chernyshov, A. Y. Finlay, L. Tomas-Aragones, M. Steinhoff, L. Manolache, N. Pustisek, C. Dessinioti, A. Svensson, S. E. Marron, A. Bewley, C. Salavastru, B. Dréno, A. Suru, D. Koumaki, D. Linder, A. W. M. Evers, D. Abeni, M. Augustin, S. S. Salek, A. Nassif, V. Bettoli, J. �¡. Szepietowski, C. C. Zouboulis
doi : 10.1111/jdv.18918
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls.
Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications
Julia-Tatjana Maul, Carole Guillet, Anna Oschmann, Lara Valeska Maul, Barbara Meier-Schiesser, Pia-Charlotte Stadler, Lars E. French, Katrin Kerl
doi : 10.1111/jdv.18879
Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of lichen planus (LP).
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events
R. Bissonnette, L. F. Eichenfield, E. Simpson, D. Thaçi, K. Kabashima, J. P. Thyssen, E. Guttman-Yassky, F. P. Nunes, M. Gamalo, F. Ahmad, M. Kuligowski, K. Sun, C. Pipper, A. W. Christensen, P. D'Angelo, M. Milutinovic, A. Guettner, J. I. Silverberg
doi : 10.1111/jdv.18881
Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment comparisons, several factors, including intercurrent events, must be taken into account.
Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis
M. O. Christensen, Y. A. Barakji, N. Loft, C. M. Khatib, A. Egeberg, S. F. Thomsen, J. I. Silverberg, C. Flohr, J. T. Maul, P. Schmid-Grendelmeier, A. S. Halling, I. Vittrup, J. P. Thyssen
doi : 10.1111/jdv.18919
Atopic dermatitis (AD) and food allergy (FA) share similar type 2 inflammation and commonly co-occur, but the precise proportion of AD patients with FA and vice versa, as well as the effect of AD disease severity on the strength of this association remains uncertain.
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study
Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Külli Kingo, Raquel Rivera Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh, Piotr Jagiello
doi : 10.1111/jdv.18846
Biologic treatments have been studied mainly in patients with a long-term history of psoriasis and previous treatment failures.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi
doi : 10.1111/jdv.18913
Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28-02-2023], after first online publication: ‘humanized monoclonal antibody’ has been changed to 'fully human monoclonal antibody' in the preceding sentence.]
Adverse reactions after oral provocation with aluminium in children with vaccination granulomas and aluminium contact allergy
Stine Skovbo Hoffmann, Jesper Elberling, Kirsten Skamstrup Hansen, Jacob P. Thyssen, Charlotte G. Mortz, Rasmus Overgaard Bach, Jeanne Duus Johansen
doi : 10.1111/jdv.18811
According to their parents, some children with aluminium contact allergy and vaccination granulomas may react to aluminium-containing foods by developing dermatitis, granuloma itch and subjective symptoms.
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7
Jonathan I. Silverberg, Eric L. Simpson, Jacob Pontoppidan Thyssen, Thomas Werfel, Tracy E. Cardillo, Stephanie Colvin, Evangeline Pierce, Yun-Fei Chen, Sherry Chen, Lawrence Eichenfield
doi : 10.1111/jdv.18816
Baricitinib demonstrated efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) in Phase 3 clinical trials.
A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis
Ida Vittrup, Niels Steen Krogh, Henrik Hedegaard Pliess Larsen, Jesper Elberling, Lone Skov, Kristina Sophie Ibler, Gregor B. E. Jemec, Charlotte G. Mortz, Rasmus Overgaard Bach, Carsten Bindslev-Jensen, Maiken Glud Dalager, Alexander Egeberg, Tove Agner, Mette Deleuran, Christian Vestergaard, Jacob Pontoppidan Thyssen
doi : 10.1111/jdv.18849
Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.
Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients
Ingrid Costedoat, Martin Wallaert, Aurelie Gaultier, Robin Vasseur, Clelia Vanhaecke, Manuelle Viguier, Charles Cordelette, Alexandre Denoyer, Marie-Christine Ferrier le Bouëdec, Adrien Coutu, Marie Lamiaux, Thi Ha Châu Tran, Jean Philippe Lacour, Valerie Elmaleh, Florence Tetart, Julie Gueudry, Marie Tauber, Francoise Giordano-Labadie, Myriam Cassagne, Audrey Nosbaum, Coralie Ouilhon, Marie Jachiet, Ramin Tadayoni, Frederic Dezoteux, Delphine Staumont-Salle, Julien Bouleau, Pierre Labalette, Serge Doan, Angele Soria, Bruno Mortemousque, Julien Seneschal, Sebastien Barbarot, FRench Atopic DErmatitis Network from the Groupe de Recherche sur l'Eczema Atopique (GREAT), France
doi : 10.1111/jdv.18932
Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination.
Prevalence and implications of type D personality in patients with alopecia areata: A marker of quality-of-life impairment and mood status disturbances, a comparative study
Manuel Sánchez-DÃÂaz, Trinidad Montero-VÃÂlchez, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Salvador Arias-Santiago
doi : 10.1111/jdv.18733
Distressed personality (or Type D personality, TDp) is a personality trait that has been associated with poor quality of life in patients suffering from a variety of skin diseases such as psoriasis or urticaria. To date the potential association between Alopecia areata (AA) and TDp has not been studied.
Outlier detection in dermatology: Performance of different convolutional neural networks for binary classification of inflammatory skin diseases
Maximilian C. Schielein, Joshua Christl, Sebastian Sitaru, Anna Caroline Pilz, Robert Kaczmarczyk, Tilo Biedermann, Tobias Lasser, Alexander Zink
doi : 10.1111/jdv.18853
Artificial intelligence (AI) and convolutional neural networks (CNNs) represent rising trends in modern medicine. However, comprehensive data on the performance of AI practices in clinical dermatologic images are non-existent. Furthermore, the role of professional data selection for training remains unknown.
Dupilumab treatment for severe atopic dermatitis in children and SARS-CoV-2 infection: A combination of triggers for psoriasis
Cristiana Colonna, Paolo Bortoluzzi, Riccardo Cavalli
doi : 10.1111/jdv.18864
Impact of SARS-CoV-2 infection in children with psoriasis: Results of a monocentric experience
Francesca Caroppo, Laura Fagotto, Jacopo Tartaglia, Roberto Mazzetto, Anna Belloni Fortina
doi : 10.1111/jdv.18874
Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study
C. Seree-aphinan, P. Suchonwanit, P. Rattanakaemakorn, C. Pomsoong, Y. Ratanapokasatit, C. Setthaudom, T. Suangtamai, K. Chanprapaph, the COVIDVAC-DERM study group
doi : 10.1111/jdv.18890
Study of covid-19 vaccine-related cutaneous adverse events following immunization and establishing a causal association
Rohini Sharma
doi : 10.1111/jdv.18891
Reply to: ‘Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab’ by Baffa et al.
L. Sun, C. Brazão, D. Mancha, L. Soares-de-Almeida, P. Filipe
doi : 10.1111/jdv.18893
Interplay between Adamantiades-Behçet's disease and COVID-19 – a case series from the German registry of Adamantiades-Behçet's disease
Anthony Lim, Andreas Altenburg, Christos C. Zouboulis
doi : 10.1111/jdv.18939
Neutrophil-to-lymphocyte ratio and the systemic immune-inflammation index as potential biomarkers of effective treatment and subclinical atherosclerotic cardiovascular disease in patients with psoriasis
Amanda Kvist-Hansen, Hannah Kaiser, Martin Krakauer, Peter M. Gørtz, Xing Wang, Christine Becker, Claus Zachariae, Peter R. Hansen, Lone Skov
doi : 10.1111/jdv.18860
Extensive furuncular myiasis in a travel returnee from Africa
Laura Rechtien, Matthias Kaufmann, Michael Sticherling
doi : 10.1111/jdv.18905
Study on hair root lipids of female androgenetic alopecia based on UPLC-Q-TOF/MS results
Xiao-qian Yu, Cong-fen He, Yan Tian
doi : 10.1111/jdv.18832
French data on the epidemiology and expert healthcare network for epidermolysis bullosa
Christine Bodemer, Louis Soussand, Arnaud Sandrin, Ahlem Khatim, Angélique Sauvestre, Nabila Elarouci, Anne-Sophie Jannot
doi : 10.1111/jdv.18826
Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening?
Julie Mac Mahon, Gregg Murray, Yvonne McCartney, Stephen Crowther, Anne-Marie Tobin, Kevin Molloy
doi : 10.1111/jdv.18807
‘Hell's itch’, a rare neurocutaneous dysesthesia, occurring in a patient with Fitzpatrick skin type IV
Martin Wyckmans, Michael Strambler, Olivier Aerts
doi : 10.1111/jdv.18910
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma
Lukas Buchacher, Georg Richtig, Marie Dernoscheg, Erika Richtig, Lukas Koch
doi : 10.1111/jdv.18871
Pharmacological treatment of cardiovascular risk factors in patients with psoriasis: A Danish nationwide study
M. S. Liljendahl, N. Loft, A. Passey, S. Wegner, A. Egeberg, L. Skov
doi : 10.1111/jdv.18873
Association between HLA-Cw6 and response to treatment with biologics in patients with psoriasis: A systematic review and meta-analysis
Mie Siewertsen, Rownaq Al-Sofi, Hajer Dridi, Gayathri D. Ajenthen, Claus Zachariae, Lone Skov, Nikolai Loft
doi : 10.1111/jdv.18870
Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis
Alessandro Pileri, Giacomo Clarizio, Corrado Zengarini, Beatrice Casadei, Elena Sabattini, Claudio Agostinelli, Pier Luigi Zinzani
doi : 10.1111/jdv.18831
All-cause and cause-specific mortality risk associated with atopic dermatitis: A Korean nationwide population-based study
Seung-Won Jung, Solam Lee
doi : 10.1111/jdv.18803
Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab
Inga Hansen, Isabel Heidrich, Finn Abeck, Julian Kött, Nina Booken, Christoffer Gebhardt, Stefan W. Schneider
doi : 10.1111/jdv.18780
Unilateral Blaschkoid-linear verrucous lichen planus under immunotherapy with pembrolizumab
Thilo Gambichler, Ocko Kautz, Rosanna Schacht, Stefanie Boms
doi : 10.1111/jdv.18759
Topical steroid-induced visual disturbances related to central serous chorioretinopathy. A potentially serious complication of dermocorticoids
Gabriel Lipsker, Mathieu Wurtz, Dan Lipsker
doi : 10.1111/jdv.18739
Unilateral facial actinic elastotic plaque: A distinct but underreported manifestation of solar elastosis
Cecilia Buján Bonino, Noelia Moreiras Arias, MarÃÂa López-Pardo Rico, Olalla Figueroa Silva, Isabel RodrÃÂguez Blanco, Carlos Aliste Santos, ÃÂ�ngel Fernández Flores, Elena Rosón López
doi : 10.1111/jdv.18694
A deep-learning algorithm to localize basal cell carcinoma foci on Mohs surgery frozen sections
Hugo Bonnefille, Marwan Abbas, Pascal Roger, François Habib, Farzaneh Masset, Marc Chaumont, Gerard Subsol, Pierre E. Stoebner
doi : 10.1111/jdv.18859
Upadacitinib for treatment-resistant Lichen amyloidosis
Farzan Solimani, Amrei Dilling, Franziska C. Ghoreschi, Alexander Nast, Kamran Ghoreschi, Katharina Meier
doi : 10.1111/jdv.18756
Oro-mammary inoculation pathway of monkeypox in a female patient
Dora Mancha, Cláudia Brazão, Paulo Filipe
doi : 10.1111/jdv.18672
Erythematous maculopapular rash in monkeypox virus infection: A retrospective case series of 30 patients
Chloé Bertin, Anne-Lise Beaumont, Marie Merlant, Morgane Mailhe, Diane Le Pluart, Laurène Deconinck, Michael Thy, Marie Cortier, Mathilde Garé, Marion Dollat, Mayda Rahi, Véronique Joly, Sylvie Lariven, Christophe Rioux, Audrey Truong, Lydia Deschamps, Valentine Marie Ferré, Charlotte Charpentier, François-Xavier Lescure, Fabrice Bouscarat, Vincent Descamps, Yazdan Yazdanpanah, Nathan Peiffer-Smadja
doi : 10.1111/jdv.18876
Monkeypox virus and secondary syphilis co-infection in a HIV-positive man
Vassilios Paparizos, Antonios Tsimpidakis, Eleni Paparizou, Eleni Gagari, Electra Nicolaidou, Alexander Stratigos
doi : 10.1111/jdv.18875
Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study
Elena Pezzolo, Luigi Naldi
doi : 10.1111/jdv.18753
Topical corticosteroid or emollient product: Which to apply first?
Christian Surber, Jasmin Robertis, Daphne Reinau
doi : 10.1111/jdv.18797
Tinea nigra with dermoscopic diagnosis: First autochthonous case in Italy?
Nunzia Di Cristo, Paola Savoia, André Luiz Rossetto, Federica Veronese, Francesca Graziola, Elisa Zavattaro
doi : 10.1111/jdv.18781
Patterns of sexual transmission of monkeypox in the current outbreak: An international survey of physicians
Ananya Sharma, Pankhuri Dudani, Somesh Gupta
doi : 10.1111/jdv.18745
AQP5, a second gene at play with CFTR in aquagenic palmoplantar keratoderma
Brian Sperelakis-Beedham, Maureen Lopez, Emmanuelle Bourrat, Natacha Gaitch, Florence Houriez, Brigitte Martinez, Isabelle Fajac, Pierre-Régis Burgel, Geoffroy Hickman, Marie-Pierre Audrézet, Delphine Gonde, Faiza Cabet, Mathieu Gerfaud-Valentin, Raphaele Nove-Josserand, Caroline Raynal, Adrien Pagin, Marie-Pierre Reboul, Alix de Becdelièvre, Thierry Bienvenu, Isabelle Callebaut, Emmanuelle Girodon
doi : 10.1111/jdv.18869
Non-invasive imaging of agminated Spitz nevi with line-field confocal optical coherence tomography
Sergio del RÃÂo-Sancho, Caroline Gallay, Sarah Ventéjou, Stephanie Christen-Zaech
doi : 10.1111/jdv.18863
The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum
Klaudia Rubas, Adam Reich, Danuta Nowicka-Suszko, Joanna Maj
doi : 10.1111/jdv.18683
Nail unit dermoscopy (onychoscopy) in the differential diagnosis of erythroderma
Magdalena Å»ychowska, Linda Tognetti
doi : 10.1111/jdv.18861
Reply to: “Dermatology's call to emergency action on climate change�
Dennis Niebel, Michael Hertl, Christina Hecker, Susanne Saha
doi : 10.1111/jdv.18677
Fears, concerns and expectations in dermatologic emergencies: A qualitative and descriptive study in a tertiary hospital
Alberto Soto-Moreno, Clara Ureña-Paniego, Trinidad Montero-VÃÂlchez, Manuel Sánchez-DÃÂaz, Pablo DÃÂaz-Calvillo, Juan ÃÂ�ngel RodrÃÂguez-Pozo, Alejandro Molina-Leyva, Antonio MartÃÂnez-López, Salvador Arias-Santiago
doi : 10.1111/jdv.18866
Diary of human monkeypox: Illustrations of the clinical course
Nikolaus Urban, Julia Valencak, Wolfgang M. Bauer, Florian Thalhammer, Alessandra Handisurya
doi : 10.1111/jdv.18802
Hyperprogression of Merkel cell carcinoma after avelumab treatment
R. Pirker, A. Fink, A. Stella, L. Stifter, C. Posch
doi : 10.1111/jdv.18887
Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study
Mercè Grau-Pérez, Laura RodrÃÂguez-Aguilar, Gaston Roustan, Fernando Alfageme
doi : 10.1111/jdv.18801
Blisters within striae as a result of hypalbuminaemia in systemic lupus erythematosus
Diego Soto-GarcÃÂa, Jose Manuel Busto Leis, Ana Carmona-Olveira, David Revilla-Nebreda, Marta de Uribe Viloria, Marta Feito-RodrÃÂguez
doi : 10.1111/jdv.18736
The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: A large-scale global cohort study
Khalaf Kridin, Noor Mruwat, Diamant Thaci, Ralf J. Ludwig
doi : 10.1111/jdv.18830
Discussing reproductive potential with transgender patients in dermatology clinics – A plea for more considerate terminology
Claire Quigley, Eoin R. Storan
doi : 10.1111/jdv.18798
Disease burden of moderate–severe atopic dermatitis by use of systemic treatment: Results from the Danish Skin Cohort
I. Vittrup, A. G. Frøstrup, S. T. Gren, S. F. Thomsen, J. J. Wu, P. Schmid-Grendelmeier, J.-T. Maul, A. Egeberg, J. P. Thyssen
doi : 10.1111/jdv.18912
Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Luca Mastorino, Federica Gelato, Irene Richiardi, Giovanni Cavaliere, Pietro Quaglino, Michela Ortoncelli, Simone Ribero
doi : 10.1111/jdv.18908
